

– 54. The method according to Claim 52, wherein the step of propagating the lymphocytes further comprises the steps of: centrifuging the cultured lymphocytes; removing the supernate from the centrifuged lymphocytes; and washing the centrifuged lymphocytes in normal saline with further centrifugation to obtain the propagated lymphocytes. –

– 55. The method according to Claim 49, wherein the step of lysing the propagated lymphocytes further comprises the steps of: suspending the propagated lymphocytes in normal saline solution; sonicating the suspended lymphocytes; and filtering the sonicated lymphocytes to obtain the lysate. –

– 56. The method according to Claim 49, wherein the step of administering the lysate to the individual further comprises the step of: determining a therapeutic dose of the lysate by skin testing.

2  
3  
Cmt  
– 57. The method according to Claim 56, wherein the step of administering the lysate to the individual comprises the step of: injecting the individual subcutaneously with the therapeutic dose of the lysate. –

– 58. The method according to Claim 57, further comprising the step of: injecting the individual subcutaneously with at least one additional therapeutic dose of the lysate. –

– 59. The method according to Claim 49, further comprising the steps of: measuring the clinical symptoms and signs of the individual before administering the lysate, and then measuring clinical symptoms and signs of the individual after administering the lysate. –

---

REMARKS

The Applicants appreciate the Examiner's helpful comments during the telephone interview with the undersigned on March 16, 1999. During the interview, the Examiner indicated that he would be willing to consider in this application claims directed to a method of treating a chemically sensitive individual with a lysate prepared as described at pages 8-10 of the specification. Accordingly, the previously-pending claims are canceled in favor of new claims 49-59.

In addition, the use of the word "normal" for the lymphocytes has been deleted throughout the specification to remove any ambiguity regarding the term and to conform the rest of the

specification to the methodology for preparing the "autogenous lymphocytic factor" from a blood sample of the individual as described at pages 8-10. No new matter has been added to the application.

Reconsideration of the application is respectfully requested. If a further telephone interview would expedite the prosecution of this application, the undersigned would appreciate a call at the number below.

DATED: April 7, 1999

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed for the HON. COMMISSIONER OF PATENTS AND TRADEMARKS, WASHINGTON, D. C. 20231 on:

April 7, 1999

Date of Deposit

Todd E. Albanesi

Name of Applicant, Assignee or Registered Representative

Todd E. Albanesi

Signature

April 7, 1999

Date of Signature

Respectfully submitted,

Todd E. Albanesi

Todd E. Albanesi, Reg. 36,426

CRUTSINGER & BOOTH

1601 Elm Street, Suite 1950

Dallas, Texas 75201-4744

(214) 220-0444; Fax (214) 220-0445

Attorneys for Applicant

vblc:\gimmy\clients\ehod.3\amend.1